Cytosolic 5'-Nucleotidase 1A As a Target of Circulating Autoantibodies in Autoimmune Diseases
- PMID: 25892010
- PMCID: PMC4887848
- DOI: 10.1002/acr.22600
Cytosolic 5'-Nucleotidase 1A As a Target of Circulating Autoantibodies in Autoimmune Diseases
Abstract
Objective: Prior investigations demonstrated that autoantibodies recognizing cytosolic 5'-nucleotidase 1A (NT5C1A) are found in 33-76% of patients with inclusion body myositis (IBM) but are observed only rarely in patients with polymyositis (PM). Thus, anti-NT5C1A may help distinguish IBM from PM. Although 4-21% of patients with dermatomyositis (DM) were shown to be anti-NT5C1A antibody positive, the clinical features of anti-NT5C1A-positive patients with DM have not been described. Furthermore, the prevalence of anti-NT5C1A antibodies in other rheumatic conditions has not been reported. This study was undertaken to define the prevalence and clinical features of anti-NT5C1A-positive patients with DM, PM, IBM, or other systemic autoimmune diseases.
Methods: We screened for anti-NT5C1A autoantibodies in patients with IBM, DM, PM, Sjögren's syndrome (SS), or systemic lupus erythematosus (SLE) and in healthy volunteers. Clinical characteristics were compared between patients who were anti-NT5C1A positive and those who were anti-NT5C1A negative.
Results: Anti-NT5C1A autoantibodies were detected in 71 (61%) of 117 patients with IBM, 2 (5%) of 42 patients with PM, 2 (5%) of 42 healthy volunteers, 24 (15%) of 159 patients with DM, 10 (23%) of 44 patients with SS, and 13 (14%) of 96 patients with SLE. No anti-NT5C1A antibody-positive patients with SS or SLE had muscle involvement. Anti-NT5C1A-positive patients with IBM had a lower prevalence of rimmed vacuoles (62% versus 83% of antibody-negative patients; P = 0.02). No differences in the clinical characteristics of antibody-positive and antibody-negative patients with DM, SS, or SLE were observed.
Conclusion: Anti-NT5C1A is a common target of circulating autoantibodies, especially in IBM but also in several different autoimmune diseases. In SLE and SS, anti-NT5C1A autoreactivity is not associated with muscle disease.
© 2016, American College of Rheumatology.
Figures
Similar articles
-
Prevalence of anti-NT5C1A antibodies in Japanese patients with autoimmune rheumatic diseases in comparison with other patient cohorts.Clin Chim Acta. 2017 Sep;472:1-4. doi: 10.1016/j.cca.2017.07.002. Epub 2017 Jul 4. Clin Chim Acta. 2017. PMID: 28687351
-
Disease specificity of autoantibodies to cytosolic 5'-nucleotidase 1A in sporadic inclusion body myositis versus known autoimmune diseases.Ann Rheum Dis. 2016 Apr;75(4):696-701. doi: 10.1136/annrheumdis-2014-206691. Epub 2015 Feb 24. Ann Rheum Dis. 2016. PMID: 25714931 Free PMC article.
-
Anti-NT5C1A autoantibodies are associated with more severe disease in patients with juvenile myositis.Ann Rheum Dis. 2018 May;77(5):714-719. doi: 10.1136/annrheumdis-2017-212436. Epub 2018 Jan 23. Ann Rheum Dis. 2018. PMID: 29363513 Free PMC article.
-
Biomarkers of inclusion body myositis.Curr Opin Rheumatol. 2013 Nov;25(6):753-62. doi: 10.1097/01.bor.0000434665.75998.f5. Curr Opin Rheumatol. 2013. PMID: 24067380 Review.
-
[Polymyositis, dermatomyositis and inclusion body myositis, nosological aspects].Presse Med. 2003 Oct 25;32(35):1656-67. Presse Med. 2003. PMID: 14631270 Review. French.
Cited by
-
Recent Updates on the Pathogenesis of Inflammatory Myopathies.Curr Rheumatol Rep. 2024 Dec;26(12):421-430. doi: 10.1007/s11926-024-01164-7. Epub 2024 Sep 24. Curr Rheumatol Rep. 2024. PMID: 39316320 Free PMC article. Review.
-
Sporadic Inclusion Body Myositis at the Crossroads between Muscle Degeneration, Inflammation, and Aging.Int J Mol Sci. 2024 Feb 27;25(5):2742. doi: 10.3390/ijms25052742. Int J Mol Sci. 2024. PMID: 38473988 Free PMC article. Review.
-
Clinical significance of anti-NT5c1A autoantibody in Korean patients with inflammatory myopathies.PLoS One. 2023 Apr 14;18(4):e0284409. doi: 10.1371/journal.pone.0284409. eCollection 2023. PLoS One. 2023. PMID: 37058449 Free PMC article.
-
Inclusion body myositis: Update on the diagnostic and therapeutic landscape.Front Neurol. 2022 Sep 27;13:1020113. doi: 10.3389/fneur.2022.1020113. eCollection 2022. Front Neurol. 2022. PMID: 36237625 Free PMC article. Review.
-
Muscle Sonography in Inclusion Body Myositis: A Systematic Review and Meta-Analysis of 944 Measurements.Cells. 2022 Feb 9;11(4):600. doi: 10.3390/cells11040600. Cells. 2022. PMID: 35203250 Free PMC article. Review.
References
-
- Yoshida S, Akizuki M, Mimori T, Yamagata H, Inada S, Homma M. The precipitating antibody to an acidic nuclear protein antigen, the Jo-1, in connective tissue diseases: a marker for a subset of polymyositis with interstitial pulmonary fibrosis. Arthritis Rheum. 1983;26:604–11. - PubMed
-
- Marguerie C, Bunn CC, Beynon HL, Bernstein RM, Hughes JM, So AK, et al. Polymyositis, pulmonary fibrosis and autoantibodies to aminoacyl-tRNA synthetase enzymes. Q J Med. 1990;77:1019–38. - PubMed
-
- Oke V, Wahren-Herlenius M. The immunobiology of Ro52 (TRIM21) in autoimmunity: a critical review. J Autoimmun. 2012;39:77–82. - PubMed
-
- Larman HB, Salajegheh M, Nazareno R, Lam T, Sauld J, Steen H, et al. Cytosolic 5′-nucleotidase 1A autoimmunity in sporadic inclusion body myositis. Ann Neurol. 2013;73:408–18. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials
